Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Seungwon YangSiyoung YangYoung Kwon JoSeungyeon KimMin Jung ChangJunjeong ChoiJae Hee CheonYun Mi YuPublished in: Therapeutic advances in chronic disease (2021)
Infliximab retreatment showed high clinical remission rates with tolerable infusion-related reactions in patients with IBD who achieved remission with initial infliximab treatment but relapsed after its discontinuation. We suggest infliximab as a viable alternative in patients with IBD who previously responded well to infliximab treatment.